However, the dual PI3K HDAC inhibitor CUDC-907 showed promising results in a phase I study in R/R DLBCL patients harboring MYC translocation or amplification [159], and is currently being evaluated in a phase II clinical trial (NCT02674750). Here, MYC is linked to diffuse large B-cell lymphoma.